Reappraisal of the clinical and biologic significance of myeloid- associated antigen expression in childhood acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 16, Issue 12, 1998, Pages 3768-3773

  Pui, Ching Hon ^a   Rubnitz, Jeffrey E ^a   Hancock, Michael L ^a   Downing, James R ^a   Raimondi, Susana C ^a   Rivera, Gaston K ^a   Sandlund, John T ^a   Ribeiro, Raul C ^a   Head, David R ^a   Relling, Mary V ^a   Evans, William E ^a   Behm, Frederick G ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD33 ANTIGEN; CD65 ANTIGEN; DNA; MICROSOMAL AMINOPEPTIDASE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CHILD; CYTOGENETICS; FLOW CYTOMETRY; GENE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SOUTHERN BLOTTING;

EID: 0032435611     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.12.3768     Document Type: Article

References (37)

1. Smith LJ, Curtis JE, Messner HA, et al: Lineage infidelity in acute leukemia. Blood 61:1138-1145, 1983
2. Pui C-H, Dahl GV, Melvin S, et al: Acute leukaemia with mixed lymphoid and myeloid phenotype. Br J Haematol 56:121-130, 1984
3. Mirro J, Zipf TF, Pui C-H, et al: Acute mixed lineage leukemia: Clinicopathologic correlations and prognostic significance. Blood 66: 1115-1123, 1985
4. Bradstock KF, Kirk J, Grimsley PG, et al: Unusual immunophenotypes in acute leukaemias: Incidence and clinical correlations. Br J Haematol 72:512-518, 1989
5. Pui C-H, Behm FG, Singh B, et al: Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 75:198-202, 1990
6. Urbano-Ispizua A, Matutes E, Villamor N, et al: Clinical significance of the presence of myeloid associated antigens in acute lymphoblastic leukaemia. Br J Hematol 75:202-207, 1990
7. Ludwig WD, Teichmann JV, Sperling C, et al: Inzidenz, klinische Merkmale und prognostische Bedeutung immunologischer Subtypen der akuten lymphoblastischen Leukämie (ALL) im Kindesalter: Erfahrungen der Therapiestudien ALL-BFM 83 und 86. Klin Pädiatr 202:243-252, 1990
8. Wiersma SR, Ortega J, Sobel E, et al: Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med 324:800-808, 1991
9. Pui C-H, Schell MJ, Riamondi SC, et al: Myeloid-antigen expression in childhood acute lymphoblastic leukemia. N Engl J Med 325:1378-1379, 1991
10. Borowitz MJ, Shuster JJ, Land VJ, et al: Myeloid-antigen expression in childhood acute lymphoblastic leukemia. N Engl J Med 325:1379-1380, 1991
11. Pui C-H, Raimondi SC, Head DR, et al: Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood 78:1327-1337, 1991
12. Kurec AS, Belair P, Stefanu C, et al: Significance of aberrant immunophenotypes in childhood acute lymphoid leukemia. Cancer 67:3081-3086, 1991
13. Cantù-Rajnoldi A, Putti C, Saitta M, et al: Co-expression of myeloid antigens in childhood acute lymphoblastic leukaemia: Relationship with the stage of differentiation and clinical significance. Br J Haematol 79:40-43, 1991
14. Drexler HG, Thiel E, Ludwig W-D: Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Leukemia 5:637-645, 1991
15. Fink F-M, Köller U, Mayer H, et al: Prognostic significance of myeloid-associated antigen expression on blast cells in children with acute lymphoblastic leukemia. Med Pediatr Oncol 21:340-346, 1993
16. Ludwig W-D, Harbott J, Bartram CR, et al: Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: Experience of the BFM Study 86. Recent Results Cancer Res 131:269-282, 1993
17. Uckun FM, Sather HN, Gaynon PS, et al: Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 90:28-35, 1997
18. Brokhardt A, Cazzaniga G, Viehmann S, et al: Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Blood 90:571-577, 1997
19. Baruchel A, Cayuela JM, Ballerini P, et al: The majority of myeloid-antigen positive (My+) childhood B-cell precursor acute lymphoblastic leukemias express TEL-AML1 fusion transcripts. Br J Haematol 99:101-106, 1997
20. Evans WE, Rodman J, Relling MV, et al: Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin Hematol 28:15-21, 1991
21. Pui C-H, Relling MV, Behm FG, et al: L-Asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 9:1680-1684, 1995
22. Pui C-H, Behm FG, Crist WM: Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 82:343-362, 1993
23. Williams DL, Harris A, Williams KJ, et al: A direct bone marrow chromosome technique for acute lymphoblastic leukemia. Cancer Genet Cytogenet 13:239-257, 1984
24. Mitelman F (ed): ISCN Guidelines for Cancer Cytogenetics, Supplement to an International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1991, p 1-54
25. Rubnitz JE, Behm FG, Pui C-H, et al: Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL and ETV6 gene abnormalities: Results of St Jude Total Therapy Study XII. Leukemia 11:1201-1206, 1997
26. Smith M, Arthur D, Camitta B, et al: Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14:18-24, 1996
27. Hayashi Y, Sugita K, Nakazawa S, et al: Karyotypic patterns in acute mixed lineage leukemia. Leukemia 4:121-126, 1990
28. Pui C-H, Frankel LS, Carroll AJ, et al: Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): A collaborative study of 40 cases. Blood 77:440-447, 1991
29. Behm FG, Smith FO, Raimondi SC, et al: Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood 87:1134-1139, 1996
30. + ALL): Immunophenotypic, ultrastructural, cytogenetic, and molecular characteristics. Leukemia 3:777-783, 1989
31. Guyotat D, Campos L, Shi Z-H, et al: Myeloid surface antigen expression in adult acute lymphoblastic leukemia. Leukemia 4:664-666, 1990
32. Nakase K, Kita K, Shiku H, et al: Myeloid antigen, CD13, CD14, and/or CD33 expression is restricted to certain lymphoid neoplasms. Am J Clin Pathol 105:761-768, 1996
33. Carbonell F, Swansbury J, Min T, et al: Cytogenetic findings in acute biphenotypic leukaemia. Leukemia 10:1283-1287, 1996
34. Kantarjian HM, Talpaz M, Dhingra K, et al: Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood 78:2411-2418, 1991
35. Suryanarayan K, Hunger SP, Kohler S, et al: Consistent involvement of the BCR gene by 9;22 breakpoint in pediatric acute leukemias. Blood 77:324-330, 1991
36. Campana D, Pui C-H: Detection of minimal residual disease in acute leukemia: Methodologie advances and clinical significance. Blood 85:1416-1434, 1995
37. Coustan-Smith E, Behm FG, Sanchez J, et al: Immunologic detection of minimal residual disease in children with acute lymphoblastic leukemia. Lancet 351:550-554, 1998